Bulgària - búlgar - БАБХ (Българска агенция по безопасност на храните)

livisto int,l s.l - Дексаметазон - инжекционен разтвор - 2.0 mg/ml - говеда, коне, котки, кучета, прасета

Unió Europea - búlgar - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - Множествена миелома - Антинеопластични средства - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Unió Europea - búlgar - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - Множествена миелома - Антинеопластични средства - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Bulgària - búlgar - Изпълнителна агенция по лекарствата

om pharma s.a. - лидокаин хидрохлорид, монохидрат довязывать калций, дексаметазон ацетат -

Bulgària - búlgar - БАБХ (Българска агенция по безопасност на храните)

vétoquinol sa - clotrimasolum, Марбофлоксацин, Дексаметазона ацетат - капки за уши, суспензия - 10 mg/ml, 3 mg/ml, 0.9 mg/ml - кучета

Bulgària - búlgar - БАБХ (Българска агенция по безопасност на храните)

veyx-pharma gmbh - Преднизолона ацетат, Дексаметазон - инжекционна суспензия - 7.50 mg/ml; 2.50 mg/ml - коне, котки, кучета

Unió Europea - búlgar - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - Множествена миелома - Антинеопластични средства - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.